SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Damian M. Herz, Brian N. Haagensen, Mark S. Christensen, Kristoffer H. Madsen, James B. Rowe, Annemette Løkkegaard, Hartwig R. Siebner, Abnormal dopaminergic modulation of striato-cortical networks underlies levodopa-induced dyskinesias in humans, Brain, 2015, 138, 6, 1658

    CrossRef

  2. 2
    John G. Nutt, Continuous levodopa infusion is better—for now, Movement Disorders, 2015, 30, 4
  3. 3
    L. Vercueil, B. Cretin, N. Boehm, Démence et syndrome parkinsonien chez une femme de 56ans, Pratique Neurologique - FMC, 2015, 6, 2, 164

    CrossRef

  4. 4
    Sherise L. Simms, Daniel P. Huettner, Sandhya Kortagere, In vivo characterization of a novel dopamine D3 receptor agonist to treat motor symptoms of Parkinson's disease, Neuropharmacology, 2015,

    CrossRef

  5. 5
    Fabrizio Stocchi, Ann Hsu, Sarita Khanna, Aaron Ellenbogen, Andreas Mahler, Grace Liang, Ulrich Dillmann, Robert Rubens, Sherron Kell, Suneel Gupta, Comparison of IPX066 with carbidopa–levodopa plus entacapone in advanced PD patients, Parkinsonism & Related Disorders, 2014, 20, 12, 1335

    CrossRef

  6. 6
    Eugénie Lhommée, Alina Batir, Jean-Louis Quesada, Claire Ardouin, Valérie Fraix, Eric Seigneuret, Stéphan Chabardès, Alim-Louis Benabid, Pierre Pollak, Paul Krack, Dopamine and the Biology of Creativity: Lessons from Parkinson’s Disease, Frontiers in Neurology, 2014, 5,

    CrossRef

  7. 7
    Jaebum Park, Mechelle M. Lewis, Xuemei Huang, Mark L. Latash, Dopaminergic modulation of motor coordinaton in Parkinson's disease, Parkinsonism & Related Disorders, 2014, 20, 1, 64

    CrossRef

  8. 8
    M. Angela Cenci, Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications, Frontiers in Neurology, 2014, 5,

    CrossRef

  9. 9
    Damian M. Herz, Brian N. Haagensen, Mark S. Christensen, Kristoffer H. Madsen, James B. Rowe, Annemette Løkkegaard, Hartwig R. Siebner, The acute brain response to levodopa heralds dyskinesias in Parkinson disease, Annals of Neurology, 2014, 75, 6
  10. 10
    Erik Cederfjäll, Nathalie Nilsson, Gurdal Sahin, Yaping Chu, Elisabeth Nikitidou, Tomas Björklund, Jeffrey H. Kordower, Deniz Kirik, Continuous DOPA synthesis from a single AAV: dosing and efficacy in models of Parkinson's disease, Scientific Reports, 2013, 3,

    CrossRef

  11. 11
    Renato P. Munhoz, Alberto J. Espay, Francesca Morgante, Jie-Yuan Li, Helio A. Teive, Emily Dunn, Eliza Gallin, Irene Litvan, Long-duration Parkinson's disease: Role of lateralization of motor features, Parkinsonism & Related Disorders, 2013, 19, 1, 77

    CrossRef

  12. 12
    Xiaoxi Zhuang, Pietro Mazzoni, Un Jung Kang, The role of neuroplasticity in dopaminergic therapy for Parkinson disease, Nature Reviews Neurology, 2013, 9, 5, 248

    CrossRef

  13. 13
    Peter Jenner, Wearing Off, Dyskinesia, and the Use of Continuous Drug Delivery in Parkinson's Disease, Neurologic Clinics, 2013, 31, 3, S17

    CrossRef

  14. 14
    Patrícia Pita Lobo, Miguel Coelho, Tiago A. Mestre, Mário M. Rosa, Joaquim J. Ferreira, Wearing-off phenomena and levodopa-induced dyskinesias in posttraumatic hemiparkinsonism, Movement Disorders, 2013, 28, 9
  15. 15
    A. Kishore, T. Popa, B. Velayudhan, T. Joseph, A. Balachandran, S. Meunier, Acute dopamine boost has a negative effect on plasticity of the primary motor cortex in advanced Parkinson's disease, Brain, 2012, 135, 7, 2074

    CrossRef

  16. 16
    Houman Homayoun, Christopher G Goetz, Facing the unique challenges of dyskinesias in Parkinson’s disease, Future Neurology, 2012, 7, 2, 127

    CrossRef

  17. 17
    John Goudreau, J Ahlskog, Parkinson's Disease, Second Edition, 2012,

    CrossRef

  18. 18
    Leo Metman, Christina Vaughan, Parkinson's Disease, Second Edition, 2012,

    CrossRef

  19. 19
    Jennifer Witt, William J. Marks, An Update on Gene Therapy in Parkinson’s Disease, Current Neurology and Neuroscience Reports, 2011, 11, 4, 362

    CrossRef

  20. 20
    Sandra Pérez-Rial, María S. García-Gutiérrez, José A. Molina, Beatriz G. Pérez-Nievas, Catherine Ledent, Carlos Leiva, Juan C. Leza, Jorge Manzanares, Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors, Neurobiology of Aging, 2011, 32, 4, 631

    CrossRef

  21. 21
    Nick H. G. Holford, John G. Nutt, Interpreting the results of Parkinson's disease clinical trials: Time for a change, Movement Disorders, 2011, 26, 4
  22. 22
    Jeff A. Beeler, Preservation of function in Parkinson's disease: What's learning got to do with it?, Brain Research, 2011, 1423, 96

    CrossRef

  23. 23
    Michael S. Remple, Courtney H. Bradenham, C. Chris Kao, P. David Charles, Joseph S. Neimat, Peter E. Konrad, Subthalamic nucleus neuronal firing rate increases with Parkinson's disease progression, Movement Disorders, 2011, 26, 9
  24. 24
    Gianni Pezzoli, Michela Zini, Levodopa in Parkinson's disease: from the past to the future, Expert Opinion on Pharmacotherapy, 2010, 11, 4, 627

    CrossRef

  25. 25
    Mario Zappia, Carlo Colosimo, Werner Poewe, Levodopa: back to the future, Journal of Neurology, 2010, 257, S2, 247

    CrossRef

  26. 26
    S. Thobois, C. Ardouin, E. Schmitt, E. Lhommée, H. Klinger, J. Xie, C. Lagrange, A. Kistner, M. Aya Kombo, V. Fleury, A. Poisson, V. Fraix, E. Broussolle, P. Pollak, P. Krack, Maladie de Parkinson : de la physiopathologie des troubles psychiques à la maîtrise du traitement dopaminergique, Revue Neurologique, 2010, 166, 10, 816

    CrossRef

  27. 27
    Angelo Antonini, K. Ray Chaudhuri, Pablo Martinez-Martin, Per Odin, Oral and Infusion Levodopa-Based Strategies for Managing Motor Complications in Patients with Parkinsonʼs Disease, CNS Drugs, 2010, 24, 2, 119

    CrossRef

  28. 28
    Manuela Contin, Paolo Martinelli, Pharmacokinetics of levodopa, Journal of Neurology, 2010, 257, S2, 253

    CrossRef

  29. 29
    Mario Zappia, Alessandra Nicoletti, The role of the long-duration response to levodopa in Parkinson’s disease, Journal of Neurology, 2010, 257, S2, 284

    CrossRef

  30. 30
    M. Angela Cenci, Christine Konradi, Recent Advances in Parkinson’s Disease: Basic Research, 2010,

    CrossRef

  31. 31
    Angelo Antonini, Apomorphine and Levodopa Infusion Therapies for Advanced Parkinson’s Disease, Journal of Movement Disorders, 2009, 2, 1, 4

    CrossRef

  32. 32
    Angelo Antonini, Eduardo Tolosa, Apomorphine and levodopa infusion therapies for advanced Parkinson’s disease: selection criteria and patient management, Expert Review of Neurotherapeutics, 2009, 9, 6, 859

    CrossRef

  33. 33
    Nuria López-Ariztegui, María Angeles Arévalo, Maria L. de Ceballos, Francisco Grandas, Central Levodopa Influx and the Clinical Motor Response to Levodopa in Patients With Parkinson Disease Complicated With Motor Fluctuations and Dyskinesias, Clinical Neuropharmacology, 2009, 32, 6, 321

    CrossRef

  34. 34
    Alan Haycox, Christophe Armand, Susana Murteira, John Cochran, Clément François, Cost Effectiveness of Rasagiline and Pramipexole as Treatment Strategies in Early Parkinsonʼs Disease in the UK Setting, Drugs & Aging, 2009, 26, 9, 791

    CrossRef

  35. 35
    Paul S. Foster, Valeria Drago, Frank Skidmore, Barry M. Skoblar, Gregory P. Crucian, Kenneth M. Heilman, Greater motor improvement in right hemibody Parkinson's patients after dopaminergic medications, Parkinsonism & Related Disorders, 2009, 15, 1, 20

    CrossRef

  36. 36
    Gurutz Linazasoro, Nadege Van Blercom, Alberto Bergaretxe, Iñaki Fernández Manchola, Enrique Laborda, José Angel Ruiz Ortega, Levodopa-Induced Dyskinesias in Parkinson Disease Are Independent of the Extent of Striatal Dopaminergic Denervation, Clinical Neuropharmacology, 2009, 32, 6, 326

    CrossRef

  37. 37
    Angelo Antonini, Per Odin, Pros and cons of apomorphine and l-dopa continuous infusion in advanced Parkinson's disease, Parkinsonism & Related Disorders, 2009, 15, S97

    CrossRef

  38. 38
    Fabrizio Stocchi, The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson's disease, Parkinsonism & Related Disorders, 2009, 15, S68

    CrossRef

  39. 39
    Mario Zappia, Aldo Quattrone, Continuous dopaminergic stimulation: Is it the answer to the motor complications of levodopa?, Movement Disorders, 2008, 23, 7
  40. 40
    Hideki Oshima, Yoichi Katayama, Chikashi Fukaya, Toshikazu Kano, Kazutaka Kobayashi, Takamitsu Yamamoto, Yutaka Suzuki, Direct inhibition of levodopa-induced beginning-of-dose motor deterioration by subthalamic nucleus stimulation in a patient with Parkinson disease, Journal of Neurosurgery, 2008, 108, 1, 160

    CrossRef

  41. 41
    Nick Holford, John G. Nutt, Disease progression, drug action and Parkinson’s disease: Why time cannot be ignored, European Journal of Clinical Pharmacology, 2008, 64, 2, 207

    CrossRef

  42. 42
    C. Marin, E. Aguilar, M. Bonastre, Effect of locus coeruleus denervation on levodopa-induced motor fluctuations in hemiparkinsonian rats, Journal of Neural Transmission, 2008, 115, 8, 1133

    CrossRef

  43. 43
    Molly M. Sturman, David E. Vaillancourt, Mark B. Shapiro, Leo Verhagen Metman, Roy A.E. Bakay, Daniel M. Corcos, Effect of short and long term STN stimulation periods on parkinsonian signs, Movement Disorders, 2008, 23, 6
  44. 44
    C. Marin, E. Aguilar, G. Mengod, R. Cortés, M.C. Rodríguez-Oroz, J.A. Obeso, Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes, Neurobiology of Disease, 2008, 32, 3, 340

    CrossRef

  45. 45
    Won Yong Lee, Won Tae Yoon, Hee Young Shin, Seong Hee Jeon, Poong-Lyul Rhee, Helicobacter pylori infection and motor fluctuations in patients with Parkinson's disease, Movement Disorders, 2008, 23, 12
  46. 46
    BERTA PASCUAL-SEDANO, JAIME KULISEVSKY, MANEL BARBANOJ, CARMEN GARCÍA-SÁNCHEZ, ANTONIA CAMPOLONGO, ALEXANDRE GIRONELL, JAVIER PAGONABARRAGA, IGNASI GICH, Levodopa and executive performance in Parkinson's disease: A randomized study, Journal of the International Neuropsychological Society, 2008, 14, 05

    CrossRef

  47. 47
    Francesca Sorbo, Alberto Albanese, Levodopa-induced dyskinesias and their management, Journal of Neurology, 2008, 255, S4, 32

    CrossRef

  48. 48
    Susan H. Fox, Anthony E. Lang, Levodopa-related motor complications—Phenomenology, Movement Disorders, 2008, 23, S3
  49. 49
    Roongroj Bhidayasiri, Daniel D. Truong, Motor complications in Parkinson disease: Clinical manifestations and management, Journal of the Neurological Sciences, 2008, 266, 1-2, 204

    CrossRef

  50. 50
    Giovanni Abbruzzese, Optimising levodopa therapy, Neurological Sciences, 2008, 29, S5, 377

    CrossRef

  51. 51
    John G. Nutt, Pharmacokinetics and pharmacodynamics of levodopa, Movement Disorders, 2008, 23, S3
  52. 52
    Roongroj Bhidayasiri, Daniel D. Truong, Reply from the authors: Motor complications in Parkinson disease: Clinical manifestations and management, Journal of the Neurological Sciences, 2008, 273, 1-2, 156

    CrossRef

  53. 53
    John Nutt, Reply: Continuous stimulation: Is it the answer to the motor complications of levodopa, Movement Disorders, 2008, 23, 7
  54. 54
    M. Dafotakis, G. R. Fink, N. Allert, D. A. Nowak, The impact of subthalamic deep brain stimulation on bradykinesia of proximal and distal upper limb muscles in Parkinson's disease, Journal of Neurology, 2008, 255, 3, 429

    CrossRef

  55. 55
    C. Marin, E. Aguilar, G. Mengod, R. Cortés, J. A. Obeso, Concomitant short- and long-duration response to levodopa in the 6-OHDA-lesioned rat: a behavioural and molecular study, European Journal of Neuroscience, 2007, 25, 1
  56. 56
    Johan Samanta, Robert A Hauser, Duodenal levodopa infusion for the treatment of Parkinson’s disease, Expert Opinion on Pharmacotherapy, 2007, 8, 5, 657

    CrossRef

  57. 57
    Emilie Lacombe, Carole Carcenac, Sabrina Boulet, Claude Feuerstein, Anne Bertrand, Annie Poupard, Marc Savasta, High-frequency stimulation of the subthalamic nucleus prolongs the increase in striatal dopamine induced by acute l-3,4-dihydroxyphenylalanine in dopaminergic denervated rats, European Journal of Neuroscience, 2007, 26, 6
  58. 58
    Virgili Pérez, Victoria Sosti, Antonia Rubio, Manel Barbanoj, José Rodríguez-Álvarez, Jaime Kulisevsky, Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration, European Journal of Pharmacology, 2007, 576, 1-3, 83

    CrossRef

  59. 59
    Angelo Antonini, New strategies in motor parkinsonism, Parkinsonism & Related Disorders, 2007, 13, S446

    CrossRef

  60. 60
    Dag Nyholm, The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease, Parkinsonism & Related Disorders, 2007, 13, S13

    CrossRef

  61. 61
    Ronald F Pfeiffer, Transdermal drug delivery in Parkinson’s disease, Aging Health, 2007, 3, 4, 471

    CrossRef

  62. 62
    Joseph Jankovic, Textbook of Clinical Neurology, 2007,

    CrossRef

  63. 63
    Nicholas H. G. Holford, Phylinda L. S. Chan, John G. Nutt, Karl Kieburtz, Ira Shoulson, Disease Progression and Pharmacodynamics in Parkinson Disease – Evidence for Functional Protection with Levodopa and Other Treatments, Journal of Pharmacokinetics and Pharmacodynamics, 2006, 33, 3, 281

    CrossRef

  64. 64
    C Warren Olanow, José A Obeso, Fabrizio Stocchi, Drug Insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease, Nature Clinical Practice Neurology, 2006, 2, 7, 382

    CrossRef

  65. 65
    Carlo Colosimo, Giovanni Fabbrini, Alfredo Berardelli, Drug Insight: new drugs in development for Parkinson's disease, Nature Clinical Practice Neurology, 2006, 2, 11, 600

    CrossRef

  66. 66
    Sen Wang, Li-fang Hu, Yun Zhang, Tao Sun, Ye-hong Sun, Su-yi Liu, Jian-hua Ding, Jie Wu, Gang Hu, Effects of Systemic Administration of Iptakalim on Extracellular Neurotransmitter Levels in the Striatum of Unilateral 6-Hydroxydopamine-Lesioned Rats, Neuropsychopharmacology, 2006, 31, 5, 933

    CrossRef

  67. 67
    Francisco Grandas, Levodopa for the treatment of Parkinson’s disease: current perspectives, Aging Health, 2006, 2, 1, 101

    CrossRef

  68. 68
    Johan Samanta, Robert A Hauser, Levodopa/carbidopa/entacapone for the treatment of Parkinson's disease, Aging Health, 2006, 2, 2, 209

    CrossRef

  69. 69
    John L. Goudreau, Medical Management of Advanced Parkinson's Disease, Clinics in Geriatric Medicine, 2006, 22, 4, 753

    CrossRef

  70. 70
    John T Slevin, Melody Ryan, Orally disintegrating carbidopa/levodopa, Future Neurology, 2006, 1, 2, 139

    CrossRef

  71. 71
    M. Angela Cenci, Martin Lundblad, Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia, Journal of Neurochemistry, 2006, 99, 2
  72. 72
    J. Bové, J. Serrats, G. Mengod, R. Cortés, E. Aguilar, C. Marin, Reversion of levodopa-induced motor fluctuations by the A2A antagonist CSC is associated with an increase in striatal preprodynorphin mRNA expression in 6-OHDA-lesioned rats, Synapse, 2006, 59, 7
  73. 73
    Dennis A. Nowak, Stephen Tisch, Marwan Hariz, Patricia Limousin, Helge Topka, John C. Rothwell, Sensory timing cues improve akinesia of grasping movements in Parkinson's disease: A comparison to the effects of subthalamic nucleus stimulation, Movement Disorders, 2006, 21, 2
  74. 74
    Won Yong Lee, Eun Ah Lee, Mi Young Jeon, Ho Young Kang, Yong Gu Park, Vesicular monoamine transporter-2 and aromatic l-amino acid decarboxylase gene therapy prevents development of motor complications in parkinsonian rats after chronic intermittent l-3,4-dihydroxyphenylalanine administration, Experimental Neurology, 2006, 197, 1, 215

    CrossRef

  75. 75
    Taro Nimura, Keiichiro Yamaguchi, Tadashi Ando, Satoshi Shibuya, Takanori Oikawa, Atsuhiro Nakagawa, Reizo Shirane, Masatoshi Itoh, Teiji Tominaga, Attenuation of fluctuating striatal synaptic dopamine levels in patients with Parkinson disease in response to subthalamic nucleus stimulation: a positron emission tomography study, Journal of Neurosurgery, 2005, 103, 6, 968

    CrossRef

  76. 76
    Mark Stacy, Annette Bowron, Mark Guttman, Robert Hauser, Kim Hughes, Jan Petter Larsen, Peter LeWitt, Wolfgang Oertel, Niall Quinn, Kapil Sethi, Fabrizio Stocchi, Identification of motor and nonmotor wearing-off in Parkinson's disease: Comparison of a patient questionnaire versus a clinician assessment, Movement Disorders, 2005, 20, 6
  77. 77
    Phylinda L. S. Chan, John G. Nutt, Nicholas H. G. Holford, Importance of Within Subject Variation in Levodopa Pharmacokinetics: A 4Year Cohort Study in Parkinson’s Disease, Journal of Pharmacokinetics and Pharmacodynamics, 2005, 32, 3-4, 307

    CrossRef

  78. 78
    Phylinda L. S. Chan, John G. Nutt, Nicholas H. G. Holford, Pharmacokinetic and Pharmacodynamic Changes During the First Four Years of Levodopa Treatment in Parkinson’s Disease, Journal of Pharmacokinetics and Pharmacodynamics, 2005, 32, 3-4, 459

    CrossRef

  79. 79
    M. Lundblad, A. Usiello, M. Carta, K. Håkansson, G. Fisone, M.A. Cenci, Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia, Experimental Neurology, 2005, 194, 1, 66

    CrossRef

  80. 80
    Orazio Schillaci, Mariangela Pierantozzi, Luca Filippi, Carlo Manni, Livia Brusa, Roberta Danieli, Giorgio Bernardi, Giovanni Simonetti, Paolo Stanzione, The effect of levodopa therapy on dopamine transporter SPECT imaging with 123I-FP-CIT in patients with Parkinson’s disease, European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 12, 1452

    CrossRef

  81. 81
    Kenneth Marek, From Neuroscience To Neurology, 2005,

    CrossRef

  82. 82
    Ali H Rajput, Mark E Fenton, Thérèse Di Paolo, Harold Sitte, Christian Pifl, Oleh Hornykiewicz, Human brain dopamine metabolism in levodopa-induced dyskinesia and wearing-off, Parkinsonism & Related Disorders, 2004, 10, 4, 221

    CrossRef

  83. 83
    C. Warren Olanow, Yves Agid, Yoshi Mizuno, Alberto Albanese, U. Bonucelli, Philip Damier, Justo De Yebenes, Oscar Gershanik, Mark Guttman, F. Grandas, Mark Hallett, Ole Hornykiewicz, Peter Jenner, R. Katzenschlager, William J. Langston, Peter LeWitt, Eldad Melamed, M.A. Mena, P.P. Michel, Catherine Mytilineou, Jose A. Obeso, Werner Poewe, Niall Quinn, R. Raisman-Vozari, Ali H. Rajput, Olivier Rascol, Christina Sampaio, Fabrizio Stocchi, Levodopa in the treatment of Parkinson's disease: Current controversies, Movement Disorders, 2004, 19, 9
  84. 84
    Rajesh Pahwa, Kelly E. Lyons, Options in the treatment of motor fluctuations and dyskinesias in Parkinson's disease: a brief review, Neurologic Clinics, 2004, 22, 3, S35

    CrossRef

  85. 85
    Nicolas Simon, Radka Gantcheva, Bernard Bruguerolle, François Viallet, The effects of a normal protein diet on LevoDOPA plasma kinetics in advanced Parkinson's disease, Parkinsonism & Related Disorders, 2004, 10, 3, 137

    CrossRef

  86. 86
    Alessandra Monge, Fabio Viselli, Fabrizio Stocchi, Luca Barbato, Andrea Bolner, Nicola Modugno, Michele Paradiso, Stefano Ruggieri, Gianpietro Nordera, Variation in the Dopaminergic Response During the Day in Parkinson Disease, Clinical Neuropharmacology, 2004, 27, 3, 116

    CrossRef

  87. 87
    Fabrizio Stocchi, Alfredo Berardelli, Laura Vacca, Luca Barbato, Alessandra Monge, Giampietro Nordera, Stefano Ruggieri, Apomorphine Infusion and the Long-Duration Response to Levodopa in Advanced Parkinson's Disease, Clinical Neuropharmacology, 2003, 26, 3, 151

    CrossRef

  88. 88
    Juha O. Rinne, Ismo Ulmanen, Myung-Sik Lee, Catechol-O-Methyl Transferase (COMT) Inhibitors in Patients with Parkinson??s Disease, American Journal of PharmacoGenomics, 2003, 3, 1, 11

    CrossRef

  89. 89
    A. Albanese, C. Colosimo, Dihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonists, Acta Neurologica Scandinavica, 2003, 107, 5
  90. 90
    Oscar Gershanik, Murat Emre, Gudrun Bernhard, Dirk Sauer, Efficacy and safety of levodopa with entacapone in Parkinson's disease patients suboptimally controlled with levodopa alone, in daily clinical practice: an international, multicentre, open-label study, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003, 27, 6, 963

    CrossRef

  91. 91
    Teus van Laar, Levodopa-Induced Response Fluctuations in Patients with Parkinson???s Disease, CNS Drugs, 2003, 17, 7, 475

    CrossRef

  92. 92
    John G. Nutt, Long-term l-DOPA therapy: challenges to our understanding and for the care of people with Parkinson's disease, Experimental Neurology, 2003, 184, 1, 9

    CrossRef

  93. 93
    Carlo Colosimo, Alessandra Craus, Noradrenergic Drugs for Levodopa-Induced Dyskinesia, Clinical Neuropharmacology, 2003, 26, 6, 299

    CrossRef

  94. 94
    Diego Garcia-Borreguero, Oscar Larrosa, Mauricio Bravo, Parkinson's disease and sleep, Sleep Medicine Reviews, 2003, 7, 2, 115

    CrossRef

  95. 95
    Eun Ah Lee, Won Yong Lee, Yong Sik Kim, Un Jung Kang, The effects of chronic L-DOPA therapy on pharmacodynamic parameters in a rat model of motor response fluctuations, Experimental Neurology, 2003, 184, 1, 304

    CrossRef

  96. 96
    J. P. Larsen, J. Worm-Petersen, Å. Sidén, A. Gordin, K. Reinikainen, M. Leinonen, The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease, European Journal of Neurology, 2003, 10, 2
  97. 97
    Peter LeWitt, Office Practice of Neurology, 2003,

    CrossRef

  98. 98
    Jaime Kulisevsky, Manel Barbanoj, Alexandre Gironell, Rosa Antonijoan, Miquel Casas, Berta Pascual???Sedano, A Double-Blind Crossover, Placebo-Controlled Study of the Adenosine A2A Antagonist Theophylline in Parkinson's Disease, Clinical Neuropharmacology, 2002, 25, 1, 25

    CrossRef

  99. 99
    Mario Zappia, Lucia Crescibene, Gennarina Arabia, Giuseppe Nicoletti, Angelo Bagal??, Loredana Bastone, Manuela Caracciolo, Simona Bonavita, Alfonso Di Costanzo, Massimo Scornaienchi, Antonio Gambardella, Aldo Quattrone, Body Weight Influences Pharmacokinetics of Levodopa in Parkinson's Disease, Clinical Neuropharmacology, 2002, 25, 2, 79

    CrossRef

  100. 100
    Dirk Deleu, Margaret G. Northway, Yolande Hanssens, Clinical Pharmacokinetic and Pharmacodynamic Properties of Drugs Used in the Treatment of Parkinson??s Disease, Clinical Pharmacokinetics, 2002, 41, 4, 261

    CrossRef

  101. 101
    K. Marek, D. Jennings, J. Seibyl, Do dopamine agonists or levodopa modify Parkinson's disease progression?, European Journal of Neurology, 2002, 9,
  102. 102
    W. H. Poewe, G. Deuschl, A. Gordin, E.-R. Kultalahti, M. Leinonen, Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal Levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study), Acta Neurologica Scandinavica, 2002, 105, 4
  103. 103
    John G. Nutt, Julie H. Carter, Eric S. Lea, Gary J. Sexton, Evolution of the response to levodopa during the first 4 years of therapy, Annals of Neurology, 2002, 51, 6
  104. 104
    R. Wenzelburger, B.-R. Zhang, S. Pohle, S. Klebe, D. Lorenz, J. Herzog, H. Wilms, G. Deuschl, P. Krack, Force overflow and levodopa-induced dyskinesias in Parkinson's disease, Brain, 2002, 125, 4, 871

    CrossRef

  105. 105
    Ubaldo Bonuccelli, Alessandro Napolitano, Paolo Del Dotto, Aldo Quattrone, Motor Response to Apomorphine in Patients With Parkinson's Disease With Long-Duration Response to Levodopa, Clinical Neuropharmacology, 2002, 25, 2, 119

    CrossRef

  106. 106
    Oksana Suchowersky, Parkinson’s disease: Medical treatment of moderate to advanced disease, Current Neurology and Neuroscience Reports, 2002, 2, 4, 310

    CrossRef

  107. 107
    J. Lyytinen, S. Kaakkola, A. Gordin, E.-R. Kultalahti, H. Teräväinen, A. Sovijärvi, The effect of COMT inhibition with entacapone on cardiorespiratory responses to exercise in patients with Parkinson's disease, Parkinsonism & Related Disorders, 2002, 8, 5, 349

    CrossRef

  108. 108
    G.F. Wooten, Anatomy and function of dopamine receptors: understanding the pathophysiology of fluctuations in Parkinson's disease, Parkinsonism & Related Disorders, 2001, 8, 2, 79

    CrossRef

  109. 109
    Eleni C. Maratos, Michael J. Jackson, Ronald K. B. Pearce, Peter Jenner, Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus), Movement Disorders, 2001, 16, 4
  110. 110
    Raúl De La Fuente-Fernández, Jian-Qiang Lu, Vesna Sossi, Salma Jivan, Michael Schulzer, James E. Holden, Chong S. Lee, Thomas J. Ruth, Donald B. Calne, A. Jon Stoessl, Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover, Annals of Neurology, 2001, 49, 3
  111. 111
    Gerlinde A. S. Metz, Tracy Farr, Mark Ballermann, Ian Q. Whishaw, Chronic levodopa therapy does not improve skilled reach accuracy or reach range on a pasta matrix reaching task in 6-OHDA dopamine-depleted (hemi-Parkinson analogue) rats, European Journal of Neuroscience, 2001, 14, 1
  112. 112
    PLS Chan, NHG Holford, DRUGTREATMENTEFFECTS ONDISEASEPROGRESSION, Annual Review of Pharmacology and Toxicology, 2001, 41, 1, 625

    CrossRef

  113. 113
    Jadwiga Najib, Entacapone: A catechol-O-methyltransferase inhibitor for the adjunctive treatment of parkinson's disease, Clinical Therapeutics, 2001, 23, 6, 802

    CrossRef

  114. 114
    Manuela Contin, Roberto Riva, Paolo Martinelli, Fiorenzo Albani, Patrizia Avoni, Agostino Baruzzi, Levodopa Therapy Monitoring in Patients With Parkinson Disease: a Kinetic–Dynamic Approach, Therapeutic Drug Monitoring, 2001, 23, 6, 621

    CrossRef

  115. 115
    John G Nutt, Motor fluctuations and dyskinesia in Parkinson's disease, Parkinsonism & Related Disorders, 2001, 8, 2, 101

    CrossRef

  116. 116
    Elina Nurmi, Hanna M. Ruottinen, Jörgen Bergman, Merja Haaparanta, Olof Solin, Pirkko Sonninen, Juha O. Rinne, Rate of progression in Parkinson's disease: A 6-[18F]fluoro-L-dopa PET study, Movement Disorders, 2001, 16, 4
  117. 117
    Jaime Kulisevsky, Carmen García-Sánchez, Marcelo L. Berthier, Manel Barbanoj, Berta Pascual-Sedano, Alexandre Gironell, Armando Estévez-González, Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: A two-year follow-up study of previously untreated patients, Movement Disorders, 2000, 15, 4
  118. 118
    C. Warren Olanow, Anthony H.V. Schapira, Olivier Rascol, Continuous dopamine-receptor stimulation in early Parkinson's disease, Trends in Neurosciences, 2000, 23, S117

    CrossRef

  119. 119
    John G. Nutt, Eric S. Lea, Laura Van Houten, Robert A. Schuff, Gary J. Sexton, Determinants of tapping speed in normal control subjects and subjects with Parkinson's disease: Differing effects of brief and continued practice, Movement Disorders, 2000, 15, 5
  120. 120
    Ubaldo Bonuccelli, Paolo Del Dotto, Claudio Lucetti, Lucia Petrozzi, Silvia Bernardini, Gianna Gambaccini, Giuseppe Rossi, Paola Piccini, Diurnal Motor Variations to Repeated Doses of Levodopa in Parkinson's Disease, Clinical Neuropharmacology, 2000, 23, 1, 28

    CrossRef

  121. 121
    Frédéric Calon, Abdallah Hadj Tahar, Pierre J. Blanchet, Marc Morissette, Richard Grondin, Martin Goulet, Jean-Pierre Doucet, George S. Robertson, Eric Nestler, Thérèse Di Paolo, Paul J. Bédard, Dopamine-receptor stimulation: biobehavioral and biochemical consequences, Trends in Neurosciences, 2000, 23, S92

    CrossRef

  122. 122
    José A. Obeso, C. Warren Olanow, John G. Nutt, Levodopa motor complications in Parkinson's disease, Trends in Neurosciences, 2000, 23, S2

    CrossRef

  123. 123
    Patricia Izurieta-Sánchez, Sophie Sarre, Guy Ebinger, Yvette Michotte, Muscarinic antagonists in substantia nigra influence the decarboxylation of l-dopa in striatum, European Journal of Pharmacology, 2000, 399, 2-3, 151

    CrossRef

  124. 124
    Leo Verhagen Metman, Spiridon Konitsiotis, Thomas N. Chase, Pathophysiology of motor response complications in Parkinson's disease: Hypotheses on the why, where, and what, Movement Disorders, 2000, 15, 1
  125. 125
    David J. Brooks, PET studies and motor complications in Parkinson's disease, Trends in Neurosciences, 2000, 23, S101

    CrossRef

  126. 126
    Jaime Kulisevsky, Role of Dopamine in Learning and Memory, Drugs & Aging, 2000, 16, 5, 365

    CrossRef

  127. 127
    Abdallah Hadj Tahar, Laurent Gr??goire, Evelyne Bangassoro, Paul J. B??dard, Sustained Cabergoline Treatment Reverses Levodopa-Induced Dyskinesias in Parkinsonian Monkeys, Clinical Neuropharmacology, 2000, 23, 4, 195

    CrossRef

  128. 128
    M.B. Stern, The early treatment of Parkinson's disease: levodopa, dopamine agonists or both, Parkinsonism & Related Disorders, 2000, 7, 1, 27

    CrossRef

  129. 129
    Robert A. Hauser, William C. Koller, Jean P. Hubble, Teresita Malapira, Karen Busenbark, C. Warren Olanow, Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease, Movement Disorders, 2000, 15, 3
  130. 130
    Stella M. Papa, Robert Desimone, Mario Fiorani, Edward H. Oldfield, Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias, Annals of Neurology, 1999, 46, 5
  131. 131
    Robert A. Hauser, Theresa A. Zesiewicz, MANAGEMENT OF EARLY PARKINSON'S DISEASE, Medical Clinics of North America, 1999, 83, 2, 393

    CrossRef

  132. 132
    Carlo Colosimo, Manuela De Michele, Motor fluctuations in Parkinson's disease: pathophysiology and treatment, European Journal of Neurology, 1999, 6, 1
  133. 133
    Joseph Jankovic, Lea Ben-Arie, Kenneth Schwartz, Kim Chen, Myrna Khan, Eugene C. Lai, Joachim K. Krauss, Robert Grossman, Movement and reaction times and fine coordination tasks following pallidotomy, Movement Disorders, 1999, 14, 1
  134. 134
    Vincenzo Bonifati, Giuseppe Meco, New, Selective Catechol-O-Methyltransferase Inhibitors as Therapeutic Agents in Parkinson’s Disease, Pharmacology & Therapeutics, 1999, 81, 1, 1

    CrossRef

  135. 135
    Ronald J. Mandel, K.G. Rendahl, Richard O. Snyder, Stuart E. Leff, Progress in Direct Striatal Delivery of l-Dopa via Gene Therapy for Treatment of Parkinson's Disease Using Recombinant Adeno-Associated Viral Vectors, Experimental Neurology, 1999, 159, 1, 47

    CrossRef

  136. 136
    Thomas B. Freeman, Dorothy E. Vawter, Paul E. Leaverton, James H. Godbold, Robert A. Hauser, Christopher G. Goetz, C. Warren Olanow, Use of Placebo Surgery in Controlled Trials of a Cellular-Based Therapy for Parkinson's Disease, New England Journal of Medicine, 1999, 341, 13, 988

    CrossRef

  137. 137
    Georg Ebersbach, Michael Stöck, Jörg Müller, Gregor Wenning, Jörg Wissel, Werner Poewe, Worsening of motor performance in patients with Parkinson's disease following transdermal nicotine administration, Movement Disorders, 1999, 14, 6
  138. 138
    Timothy Brannan, Alla Prikhojan, Melvin D Yahr, Effects of repeated administration of l-DOPA and apomorphine on circling behavior and striatal dopamine formation, Brain Research, 1998, 784, 1-2, 148

    CrossRef

  139. 139
    Anthony E. Lang, Andres M. Lozano, Parkinson's Disease, New England Journal of Medicine, 1998, 339, 16, 1130

    CrossRef

  140. 140
    A Hoffman, Pharmacodynamic aspects of sustained release preparations, Advanced Drug Delivery Reviews, 1998, 33, 3, 185

    CrossRef

  141. 141
    Iñaki F. Trocóniz, Tarja H. Naukkarinen, Hanna M. Ruottinen, Urpo K. Rinne, Ariel Gordin, Mats O. Karlsson, Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone, Clinical Pharmacology & Therapeutics, 1998, 64, 1
  142. 142
    Richard Torstenson, Per Hartvig, Bengt Långström, Göran Westerberg, Joakim Tedroff, Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease, Annals of Neurology, 1997, 41, 3
  143. 143
    Christopher G. Goetz, New Strategies with Dopaminergic Drugs: Modified Formulations of Levodopa and Novel Agonists, Experimental Neurology, 1997, 144, 1, 17

    CrossRef

  144. 144
    Matthew B. Stern, Andrew Freese, Parkinson's Disease: The Case for Novel Treatment Strategies, Experimental Neurology, 1997, 144, 1, 2

    CrossRef

  145. 145
    Howard I. Hurtig, Problems with Current Pharmacologic Treatment of Parkinson's Disease, Experimental Neurology, 1997, 144, 1, 10

    CrossRef

  146. 146
    John G. Nutt, Julie H. Carter, Laura Van Houten, William R. Woodward, Short- and long-duration responses to levodopa during the first year of levodopa therapy, Annals of Neurology, 1997, 42, 3
  147. 147
    Mark D. Lindner, Melissa A. Plone, Ted D. Mullins, Shelley R. Winn, Susan E. Chandonait, Jennifer A. Stott, Thomas J. Blaney, Sandy S. Sherman, Dwaine F. Emerich, Somatic Delivery of Catecholamines in the Striatum Attenuate Parkinsonian Symptoms and Widen the Therapeutic Window of Oral Sinemet in Rats, Experimental Neurology, 1997, 145, 1, 130

    CrossRef

  148. 148
    Joakim M. Tedroff, The Neuroregulatory Properties of L-DOPA. A Review of the Evidence and Potential Role in the Treatment of Parkinson's Disease, Reviews in the Neurosciences, 1997, 8, 3-4

    CrossRef

  149. 149
    A.H. Rajput, Ryan J. Uitti, Alex H. Rajput, Kenneth P. Offord, Timely levodopa (LD) administration prolongs survival in Parkinson's disease, Parkinsonism & Related Disorders, 1997, 3, 3, 159

    CrossRef